Legend Biotech shares climbed 6% to $21.88 Tuesday after the company posted a Q2 2026 revenue beat and its first quarter of company-wide profitability. CARVYKTI net sales rose 50% to $657 million, and management reaffirmed a peak sales target above $5 billion for the CAR-T therapy.
Legend Biotech shares climbed 6% to $21.88 Tuesday midday after the company reported Q2 2026 results pairing a revenue beat with its first quarter of profitability company-wide. The stock is still down 41% over the past year, so the reaction reads as validation of the CARVYKTI ramp that anchors the investment case.
Revenue Beat Turns Into a Profit
Legend Biotech posted total revenue of $387.5 million, up 52% year over year, topping the $362.81 million estimate analysts had modeled. Adjusted EPS came in at $0.16, more than double the roughly $0.07 analyst consensus.
As a result, the company booked net income of $33.2 million versus a net loss of $125.4 million a year earlier, alongside adjusted net income of $63.1 million and operating income of $57.7 million. Unrealized FX losses also fell, dropping to $0.6 million in Q2 2026 from $110.9 million a year earlier, even as operating gains did most of the work.
The balance sheet strengthened too: Legend Biotech ended the quarter with approximately $965 million in cash, cash equivalents and time deposits and no long-term debt, boosted by about $212 million of net proceeds from a June public offering.
CARVYKTI Sales Climb 50%
CARVYKTI net trade sales reached $657 million, up 50% year over year, with U.S. sales up 32% and ex-U.S. sales up 128%. The therapy is now available across 348 treatment sites in 19 markets, with Ireland the most recent launch.
Management reiterated peak annual sales potential above $5 billion for CARVYKTI, keeping it the central pillar of the investment case. However, Bristol Myers Squibb markets Abecma, the other approved BCMA CAR-T therapy, and competitive positioning against it remains a key debate since Legend Biotech is still largely a single-product commercial story.
Pipeline Progress and a Leadership Question
Legend Biotech also reported first clinical proof-of-concept for LB2501, an investigational CAR-T therapy, showing a 100% overall response rate and an 83.3% complete response rate at the higher dose level in relapsed or refractory B-cell non-Hodgkin lymphoma. A U.S. IND filing is planned by year-end. Novartis licenses the separate LB2102 DLL3-targeted CAR-T program, which lets Legend Biotech concentrate spending on wholly-owned candidates.
Meanwhile, Alan Bash is serving as interim CEO following the departure of former CEO Ying Huang last month. Bash said in the earnings release: "we remain confident in our ability to advance innovation and progress toward company-wide profitability".
Wall Street's setup still leans constructive: the consensus analyst target on LEGN sits at $52.10, well above where shares trade today, with five strong buys, six buys, and four holds. Sector conditions are supportive too, with the iShares Biotechnology ETF up 18.5% year to date, keeping the backdrop friendly for biotech beats.
Source: 24/7 Wall St.
Trading involves risk.
Risk Disclaimer
